Logo

Shimadzu Will Market, Distribute LumiCyte Technology in Japan

Jun 21, 2002

NEW YORK, June 21 - LumiCyte next week will announce that it has brought on Shimadzu to market and distribute its SELDI-based protein-mapping technology in Japan.

 

The deal, which marks LumiCyte's entrée into a market other than the US, comes with a "multi-million dollar equity investment by Shimadzu.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.